Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size

Acute Respiratory Distress Syndrome Treatment Market Analysis

The Global Acute Respiratory Distress Syndrome Treatment Market size is estimated at USD 3.26 billion in 2024, and is expected to reach USD 4.30 billion by 2029, growing at a CAGR of 5.65% during the forecast period (2024-2029).

According to the clinical data of COVID-19 patients with severe infection, radiologic evidence of lung edema shows that symptoms of Acute Lung Injury (ALI) can progress to hypoxemia and possibly ARDS in COVID-19 patients. According to the study titled "Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management" published in the Pneumonia in December 2021, about one-third or (33%) of hospitalized patients experience ARDS. Additionally, ARDS is present in almost 3/4 (or 75%) of COVID-19 patients admitted to the intensive care unit. ARDS patients with COVID-19 have a poor prognosis and a high mortality rate. Thus, the acute respiratory distress market has been significantly impacted by COVID-19.

The market for acute respiratory distress syndrome (ARDS) is being driven by factors such as the rising prevalence and incidence of acute lung injury, a wide range of ARDS risk factors, and an increase in the number of patients with COVID-19 who have ARDS. The global market for acute respiratory distress syndrome (ARDS) is also expected to grow as a result of factors such as the prevalence of diseases linked to lifestyle choices, air pollution, and accidents that cause ARDS. According to the study titled "Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults" by Mark D Siegel published in June 2022, around 190,000 ARDS cases are reported annually in the United States. The incidence rose with patient age, rising from 16 per 100,000 person-years for those aged 15 to 19 to 306 per 100,000 person-years for those aged 75 to 84. Moreover, the growing geriatric population supports market growth. For instance, as per United Nations Department of Economic and Social Affairs report titled 'World Population Ageing 2020 Highlights' mentioned that there were 727 million persons aged 65 years or over in the world in 2020. It is expected that the population is more than double and reaches nearly 1.5 billion in 2050. Since the older population is at high risk of getting respiratory and other illnesses, it is expected to generate the need for treatment, thereby driving the market's growth.

Furthermore, increasing healthcare spending and market participants' strategic initiatives present a growth opportunity for the global acute respiratory distress syndrome (ARDS) market. For Instance, In June 2020, NeuroRx, in partnership with Relief Therapeutics, announced that the United States Food and Drug Administration awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19. Additionally, in November 2020, Novartis declared that it had entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, market, and manufacture remestemcel-L to treat acute respiratory distress syndrome.

Thus, all aforementioned factors are expected to boost the market growth over the forecast period, However, high costs associated with the treatment and devices and regulatory complication may restraint the market growth.